LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global Point-of-Care Testing (POCT) Market to Surpass USD 55 Billion by 2030

By LabMedica International staff writers
Posted on 19 Apr 2022
Print article
Image: Rising prevalence of chronic diseases is driving the global POCT market (Photo courtesy of Pexels)
Image: Rising prevalence of chronic diseases is driving the global POCT market (Photo courtesy of Pexels)

The global point of care testing (POCT) market was valued at USD 29.47 billion in 2020 and is expected to grow at a CAGR of 6.5% from 2021 to 2030 to reach USD 55.27 billion by 2030, driven by a rise in the prevalence of chronic diseases such as diabetes, rheumatism, and cancer and several supportive initiatives implemented by government and non-government organizations. However, stringent government regulations for the approval of POCT devices and reimbursement issues are expected to restrain the market growth. On the other hand, technological advancements in POCT devices and the advent of home-based POCT devices will present new growth opportunities in the coming years.

These are the latest findings of Allied Market Research (Dublin, Ireland), a full-service market research and business-consulting firm.

Owing to surge in the prevalence of COVID-19 infection across the world, there has been an increase in the demand for POCT kits such as COVID-19 rapid kits for the detection of coronavirus, thereby driving the growth of the POCT market during the pandemic. There were increased development activities of various testing and monitoring kits during this period. However, lockdown restrictions and supply chain disruptions posed distribution challenges and created a supply-chain gap.

Based on product, the glucose monitoring kits segment accounted for the highest share of the POCT market in 2020, contributing to more than two-fifths of the market, and is expected to maintain its leadership position until 2030. This can be attributed to a rise in the prevalence of target diseases such as diabetes. However, the infectious diseases testing kits segment is estimated to register the highest CAGR of 12.7% from 2021 to 2030, owing to a rise in the prevalence of infectious diseases such as hepatitis, influenza, COVID-19, & human immunodeficiency virus (HIV).

Based on end-user, the professional diagnostic centers segment held the highest share of the POCT market in 2020, contributing to more than half of the market, and is expected to maintain its dominance in terms of revenue throughout the forecast period. This can be attributed to access to novel diagnostic technologies, improvement in healthcare coverage, and affordability. However, the research laboratories segment is expected to register the fastest CAGR of 7.8% from 2021 to 2030 due to a surge in the prevalence of various chronic and infectious diseases globally.

Geographically, North America held the highest share of the global POCT market in terms of revenue in 2020, accounting for around two-fifths of the market, and is projected to maintain its leadership position until 2030. This can be attributed to the surge in COVID-19 cases in the US and Canada. However, Asia-Pacific is estimated to register the fastest CAGR of 7.8% during the forecast period due to the development of healthcare infrastructure and high prevalence of chronic and targeted diseases such as diabetes, cancer, and others, in the region.

Related Links:
Allied Market Research 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more